Page 5 - Biontech Se News Today

BioNTech stock has dropped 36% this year as demand fell for its Covid-19 vaccines produced with Pfizer.

By Helena Smolak BioNTech warned that full-year revenue from Covid-19 vaccines would be weaker than previously expected and reduced its spending plans. The...

Pfizer and BioNTech said an early trial of a combined Covid-19 and influenza vaccine had produced positive data. The companies are set for a race with...

Pfizer, Moderna and Novavax believe combination shots will simplify the process for people to protect themselves against Covid and the flu.

MAINZ, Germany, October 23, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the...

Program updates include new data for investigational CAR-T and ex-vivo T cell therapies, a novel ADC, a FixVac off-the-shelf mRNA cancer vaccine, and a...

These are the stocks posting the largest moves in premarket trading.

The vagaries of the COVID-19 market and the uncertainties of pandemic fatigue are hitting some biopharma companies in the pocketbook, at least for now. Due to lower-than-expected revenues from its COVID-19 Comirnaty vaccine and antiviral Paxlovid (nirmatrelvir/ritonavir), Pfizer Inc. reduced its 2023 revenue guidance by $9 billion after hours Oct. 13, saying it now anticipates full-year 2023 revenues to range from $58 billion to $61 billion – down from its previous guidance range of $67 billio...

The U.S. government will return treatments of the company's Paxlovid drug as coronavirus vaccination rates fall.

These are the stocks posting the largest moves midday.